According to a new market report published by Lucintel, the future of the recombinant DNA technology market looks promising with opportunities in biotechnology & pharmaceutical companies and academic & government research institutes. The global recombinant DNA technology market is expected to grow with a CAGR of 7% from 2020 to 2025. The major drivers for this market are increasing adoption of genetically modified crops & biopesticides and the rising burden of chronic diseases.
To download report brochure, please go to https://www.lucintel.com/recombinant-dna-technology-market.aspx and click "download brochure" tab from the menu
Recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism and product. In this market, medical and non-medical are the major product segments. Lucintel forecasts that medical will remain the largest product segment over the forecast period, as it has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes.
Within this market, pharmaceutical & biotechnology companies will remain the largest end use segment over the forecast period, as the techniques accelerate their drug development capabilities. Moreover, the end products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity.
North America will remain the largest region over the forecast period because the presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven the regional growth.
Roche, Profacgen, Amgen, Novartis, GenScript, Pfizer, Novo Nordisk, Biogen, Biocon, GlaxoSmithKline, New England Biolabs, Cibus, Monsanto, and Horizon Discovery are among the major suppliers in the global recombinant DNA technology market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global recombinant DNA technology market by product, component, application, end use, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Recombinant DNA Technology Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global recombinant DNA technology market by product, component, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Therapeutic Agent
Human Protein
Vaccine
Biotech Crops
Specialty Chemicals
Others
By Component [Value ($ Million) shipment analysis for 2014 – 2025]:
Mammalian
Bacteria
Yeast
Baculovirus / Insects
Others
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Food & Agriculture
Health & Diseases
By End Use [Value ($ Million) shipment analysis for 2014 – 2025]:
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
Spain
Italy
France
This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.